Barrett's esophagus

New England Journal of Medicine

Volumn 346, Issue 11, 2002, Pages 836-842

  Spechler, Stuart Jon ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; ANTIULCER AGENT;

ADULT; BARRETT ESOPHAGUS; CASE REPORT; DISEASE COURSE; DYSPLASIA; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; LOWER ESOPHAGUS SPHINCTER; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STATISTICAL MODEL; STOMACH FUNDOPLICATION; ALGORITHM; ESOPHAGOSCOPY; ESOPHAGUS; MIDDLE AGED; PATHOLOGY;

ALGORITHMS; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; ESOPHAGOSCOPY; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES;

EID: 0037075991     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp012118     Document Type: Review

References (57)

1. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?
2. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
3. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
4. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction
5. Prevalence of metaplasia at the gastro-oesophageal junction
6. Short segment Barrett's esophagus - The need for standardization of the definition and of endoscopic criteria
7. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus
8. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus
9. Epidemiology of columnar-lined esophagus and adenocarcinoma
10. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data
11. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: A systematic review
12. Life expectancy and cancer risk in patients with Barrett's esophagus: A prospective controlled investigation
13. Endoscopic surveillance of Barrett's esophagus: Does it help?
14. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients
15. Natural history of early esophageal squamous carcinoma and early adenocarcinoma of the gastric cardia in the People's Republic of China
16. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: Observational study
17. Cost effectiveness of detecting Barrett's cancer
18. Endoscopic surveillance of Barrett's esophagus: A cost-effectiveness comparison with mammographic surveillance for breast cancer
19. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk
20. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma
21. Screening for high-grade dysplasia in gastroesophageal reflux disease: Is it cost-effective?
22. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
23. Antireflux surgery: Indications, preoperative evaluation, and outcome
24. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
25. Gastroesophageal reflux disease in patients with columnar-lined esophagus
26. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus
27. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors
28. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects
29. Dynamic effects of acid on Barrett's esophagus: An ex vivo proliferation and differentiation model
30. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure
31. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus
32. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression
33. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus
34. Endoscopic regression of Barrett's oesophagus during omeprazole treatment: A randomised double blind study
35. Squamous islands in Barrett's esophagus: What lies underneath?
36. Biomarker studies in reversed Barrett's esophagus
37. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids
38. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial
39. Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery
40. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
41. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression
42. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation
43. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia
44. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
45. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets
46. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma
47. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia
48. Long-term follow-up of Barrett's high-grade dysplasia
49. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression
50. Effects of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer
51. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: A review
52. Photodynamic therapy for Barrett's esophagus: Follow-up in 100 patients
53. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma
54. Esophageal cancer: Screening and surveillance: Results of a consensus conference held at the VIth World Congress of the International Society for Diseases of the Esophagus
55. The role of endoscopy in the surveillance of premalignant conditions of the upper gastrointestinal tract
56. The role of endoscopy in the management of GERD: Guidelines for clinical application
57. Management of Barrett's esophagus